Terms: = Bone cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Treatment
20 results:
1. A predictive scoring model to select suitable patients for surgery on primary tumor in metastatic esophageal cancer.
Wei L; Xu J; Hu X; Xie Y; Lyu G
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1898. PubMed ID: 37702247
[TBL] [Abstract] [Full Text] [Related]
2. Clinical model of pulmonary metastasis in patients with osteosarcoma: A new multiple machine learning-based risk prediction.
Su Z; Huang F; Yin C; Yu Y; Yu C
J Orthop Surg (Hong Kong); 2023; 31(2):10225536231177102. PubMed ID: 37288764
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of Prebiotic Properties of Galactooligosaccharides Produced by Transgalactosylation Using Partially Purified β-Galactosidase from Enterobacter aerogenes KCTC2190.
Maity M; Majumdar S; Bhattacharyya DK; Bhowal J; Das A; Barui A
Appl Biochem Biotechnol; 2023 Apr; 195(4):2294-2316. PubMed ID: 35841532
[TBL] [Abstract] [Full Text] [Related]
4. MRI for evaluation of preoperative chemotherapy in osteosarcoma.
Yildirim O; Al Khatalin M; Kargin OA; Camurdan VB
Radiography (Lond); 2022 Aug; 28(3):593-604. PubMed ID: 35537246
[TBL] [Abstract] [Full Text] [Related]
5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract] [Full Text] [Related]
6. Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung cancer: What to Expect in the Real World.
Pelizzari G; Cortiula F; Giavarra M; Bartoletti M; Lisanti C; Buoro V; Cattaneo M; Rossetto C; Rizzato S; Puglisi F; Macerelli M; Fasola G; Follador A
Drugs Aging; 2020 Sep; 37(9):677-689. PubMed ID: 32681401
[TBL] [Abstract] [Full Text] [Related]
7. Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National cancer Database Analysis.
Ghiassi-Nejad Z; Ru M; Moshier E; Chang S; Jagannath S; Dharmarajan K
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):310-319. PubMed ID: 30878315
[TBL] [Abstract] [Full Text] [Related]
8. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary bone Metastatic Prostate cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract] [Full Text] [Related]
9. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract] [Full Text] [Related]
10. Continued treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast cancer Metastatic to bone: The OPTIMIZE-2 Randomized Clinical Trial.
Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
[TBL] [Abstract] [Full Text] [Related]
11. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
O'Shaughnessy J; Campone M; Brain E; Neven P; Hayes D; Bondarenko I; Griffin TW; Martin J; De Porre P; Kheoh T; Yu MK; Peng W; Johnston S
Ann Oncol; 2016 Jan; 27(1):106-13. PubMed ID: 26504153
[TBL] [Abstract] [Full Text] [Related]
12. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract] [Full Text] [Related]
13. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Hue TF; Cummings SR; Cauley JA; Bauer DC; Ensrud KE; Barrett-Connor E; Black DM
JAMA Intern Med; 2014 Oct; 174(10):1550-7. PubMed ID: 25111880
[TBL] [Abstract] [Full Text] [Related]
14. Novel target genes responsive to apoptotic activity by Ocimum gratissimum in human osteosarcoma cells.
Lin CC; Chao PY; Shen CY; Shu JJ; Yen SK; Huang CY; Liu JY
Am J Chin Med; 2014; 42(3):743-67. PubMed ID: 24871663
[TBL] [Abstract] [Full Text] [Related]
15. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
Valachis A; Polyzos NP; Coleman RE; Gnant M; Eidtmann H; Brufsky AM; Aft R; Tevaarwerk AJ; Swenson K; Lind P; Mauri D
Oncologist; 2013; 18(4):353-61. PubMed ID: 23404816
[TBL] [Abstract] [Full Text] [Related]
16. Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients.
Buddingh EP; Ruslan SE; Berghuis D; Gelderblom H; Anninga JK; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Cancer Immunol Immunother; 2012 Jun; 61(6):941-7. PubMed ID: 22402907
[TBL] [Abstract] [Full Text] [Related]
17. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
[TBL] [Abstract] [Full Text] [Related]
18. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract] [Full Text] [Related]
19. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
[TBL] [Abstract] [Full Text] [Related]
20. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract] [Full Text] [Related]
